Polycyclic Compounds: Ideal Drug Scaffolds for the Design of Multiple Mechanism Drugs?

Neurotherapeutics

Volumn 6, Issue 1, 2009, Pages 175-186

  Van der Schyf, Cornelis J ^a   Geldenhuys, Werner J ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Multifunctional drugs; pentacycloundecane; polycyclic compounds

Indexed keywords

ADAMANTANE DERIVATIVE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR AGONIST; CHELATING AGENT; CITALOPRAM; DULOXETINE; HLA 20; LADOSTIGIL; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER UPTAKE INHIBITOR; NGP1 01; PENTACYCLOUNDECYLAMINE DERIVATIVE; POLYCYCLIC HYDROCARBON; PRC 200; SAXAGLIPTIN; TRIQUINYLAMINE DERIVATIVE; TRISHOMOCUBANE DERIVATIVE; UNCLASSIFIED DRUG; VK 28;

ALZHEIMER DISEASE; ARTICLE; DIELS ALDER REACTION; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADAMANTANE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; POLYCYCLIC COMPOUNDS; PSYCHOTROPIC DRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57749105458     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.10.037     Document Type: Article

References (81)

1. Youdim M.B., and Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26 (2005) 27-35
2. Van der Schyf C.J., Gal S., Geldenhuys W.J., and Youdim M.B. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. Expert Opin Investig Drugs 15 (2006) 873-886
3. Morphy R., and Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48 (2005) 6523-6543
4. Morphy R., Kay C., and Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 9 (2004) 641-651
5. Van der Schyf C.J., Geldenhuys W.J., and Youdim M.B. Multifunctional neuroprotective drugs for the treatment of cognitive and movement impaired disorders, including Alzheimer's and Parkinson's diseases. Drugs of the Future 31 (2006) 447-460
6. Gurwitz J.H. Polypharmacy: a new paradigm for quality drug therapy in the elderly?. Arch Intern Med 164 (2004) 1957-1959
7. Bymaster F.P., Beedle E.E., Findlay J., et al. Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett 13 (2003) 4477-4480
8. Liang Y., Shaw A.M., Boules M., et al. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J Pharmacol Exp Ther 327 (2008) 573-583
9. Shaw A.M., Boules M., Zhang Y., et al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol 555 (2007) 30-36
10. Carlier P.R., Lo M.M., Lo P.C., et al. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett 8 (1998) 487-492
11. Gal S., Zheng H., Fridkin M., and Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95 (2005) 79-88
12. Zheng H., Weiner L.M., Bar-Am O., et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13 (2005) 773-783
13. Zecca L., Youdim M.B., Riederer P., Connor J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
14. Jacobson K.A., Xie R., Young L., Chang L., and Liang B.T. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. J Biol Chem 275 (2000) 30272-30279
15. Karellas P., McNaughton M., Baker S.P., and Scammells P.J. Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands. J Med Chem 51 (2008) 6128-6137
16. Maruyama W., Takahashi T., Youdim M., and Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109 (2002) 467-481
17. Maruyama W., Yamamoto T., Kitani K., Carrillo M.C., Youdim M., and Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 116 (2000) 181-191
18. Naoi M., Maruyama W., Yagi K., and Youdim M. Anti-apoptotic function of L-(-)deprenyl (Selegiline) and related compounds. Neurobiology (Bp) 8 (2000) 69-80
19. Naoi M., Maruyama W., Youdim M.B., Yu P., and Boulton A.A. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 11 (2003) 175-181
20. Youdim M.B. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 3 (2006) 541-550
21. Youdim M.B., and Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147 suppl 1 (2006) S287-S296
22. Youdim M.B., and Weinstock M. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev 123 (2002) 1081-1086
23. Bar-Am O., Weinreb O., Amit T., and Youdim M.B. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci (2008) Aug 27; [Epub ahead of print]
24. Yogev-Falach M., Bar-Am O., Amit T., Weinreb O., and Youdim M.B. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. Faseb J 20 (2006) 2177-2179
25. Sagi Y., Weinstock M., and Youdim M.B. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J Neurochem 86 (2003) 290-297
26. Maruyama W., Weinstock M., Youdim M.B., Nagai M., and Naoi M. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341 (2003) 233-236
27. Weinstock M., Poltyrev T., Bejar C., and Youdim M.B. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) 160 (2002) 318-324
28. Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M.B., and Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci 939 (2001) 148-161
29. Weinstock M., Bejar C., Wang R.H., et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Transm Suppl (2000) 157-169
30. Bachurin S., Bukatina E., Lermontova N., et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 939 (2001) 425-435
31. Doody R.S., Gavrilova S.I., Sano M., et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372 (2008) 207-215
32. Lermontova N.N., Redkozubov A.E., Shevtsova E.F., Serkova T.P., Kireeva E.G., and Bachurin S.O. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 132 (2001) 1079-1083
33. Grigorev V.V., Dranyi O.A., and Bachurin S.O. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 136 (2003) 474-477
34. Cookson R.C., Grundwell E., and Hudec J. Synthesis of cage-like molecules by irradiation of Diels-Alder adducts. Chem Ind (1958) 1003-1004
35. Sasaki T., Eguchi S., Kiriyama T., and Hiroaki O. Studies on hetero-cage compounds-VI transannular cyclizations in pentacyclo[6.2.1.0.(2,7)0.(4,10)0.(5,9)]undecan-3,6-dione system. Tetrahedron 30 (1974) 2707-2712
36. Sasaki T., Eguchi S., and Kiriyama T. A facile synthesis of mono-oxa- and -aza-bird-cage compounds transannular cyclization. Tetrahedron Lett 12 (1971) 2651-2654
37. Marchand A.P., Arney B.E., Dave P.R., Satyanarayana N., Watson W.H., and Nagl A. Transannular cyclizations in the pentacyclo[5.4.0.02,6.03,10.05,9]undecane-8,11-dione system. A reinvestigation. J Org Chem 53 (1988) 2644-2647
38. Geldenhuys W.J., Malan S.F., Bloomquist J.R., Marchand A.P., and Van der Schyf C.J. Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med Res Rev 25 (2005) 21-48
39. Van der Schyf C.J., Squier G.J., and Coetzee W.A. Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. Pharmacol Res Commun 18 (1986) 407-417
40. Kiewert C., Hartmann J., Stoll J., Thekkumkara T.J., Van der Schyf C.J., and Klein J. NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels. Neurochem Res 31 (2006) 395-399
41. Malan S.F., Van der Walt J.J., and Van der Schyf C.J. Structure-activity relationships of polycyclic aromatic amines with calcium channel blocking activity. Arch Pharm (Weinheim) 333 (2000) 10-16
42. Malan S.F., Dyason K., Wagenaar B., Van Der Walt J.J., and Van Der Schyf C.J. The structure and ion channel activity of 6-benzylamino-3-hydroxyhexa-cyclo[6.5.0.0(3,7).0(4,12).0(5,10).0(9,13]trid ecane. Arch Pharm (Weinheim) 336 (2003) 127-133
43. Thomas D., Wendt-Nordahl G., Rockl K., Ficker E., Brown A.M., and Kiehn J. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 297 (2001) 753-761
44. Nadler G., Faivre J.F., Forest M.C., et al. Synthesis, electrophysiological properties and analysis of structural requirements of a novel class of antiarrhythmic agents with potassium and calcium channel blocking properties. Bioorg Med Chem 6 (1998) 1993-2011
45. O'Neill M.J., Bath C.P., Dell C.P., et al. Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol 332 (1997) 121-131
46. Geldenhuys W.J., Malan S.F., Bloomquist J.R., and Van der Schyf C.J. Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor. Bioorg Med Chem 15 (2007) 1525-1532
47. Bresink I., Danysz W., Parsons C.G., and Mutschler E. Different binding affinities of NMDA receptor channel blockers in various brain regions-indication of NMDA receptor heterogeneity. Neuropharmacology 34 (1995) 533-540
48. Mdzinarishvili A., Geldenhuys W.J., Abbruscato T.J., Bickel U., Klein J., and Van der Schyf C.J. NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci Lett 383 (2005) 49-53
49. Hao J., Mdzinarishvili A., Abbruscato T.J., et al. Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. Brain Res 1196 (2008) 113-120
50. Geldenhuys W.J., Terre'Blanche G., Van der Schyf C.J., and Malan S.F. Screening of novel pentacyclo-undecylamines for neuroprotective activity. Eur J Pharmacol 458 (2003) 73-79
51. Carvey P.M., Punati A., and Newman M.B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 15 (2006) 239-250
52. Przedborski S., Tieu K., Perier C., and Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36 (2004) 375-379
53. Jakowec M.W., and Petzinger G.M. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 54 (2004) 497-513
54. Kornhuber J., Schoppmeyer K., and Riederer P. Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex. Neurosci Lett 163 (1993) 129-131
55. Nguyen V.H., Kassiou M., Johnston G.A., and Christie M.J. Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes. Eur J Pharmacol 311 (1996) 233-240
56. Kassiou M., Nguyen V.H., Knott R., Christie M.J., and Hambley T.W. Trishomocubanes, a new class of selective and high affinity ligands for the sigma binding site. Bioorg Med Chem Lett 6 (1996) 595-600
57. Liu X., Banister S.D., Christie M.J., et al. Trishomocubanes: novel sigma ligands modulate cocaine-induced behavioural effects. Eur J Pharmacol 555 (2007) 37-42
58. Liu X., Nuwayhid S., Christie M.J., Kassiou M., and Werling L.L. Trishomocubanes: novel sigma-receptor ligands modulate amphetamine-stimulated [3H]dopamine release. Eur J Pharmacol 422 (2001) 39-45
59. Kent G.J., Godleski S.A., Osawa E., and Schleyer PvR. Syntheses and relative stability of (D3)-trishomocubane (pentacyclo[6.3.0.02,6.03,10.05,9]undecane), the pentacycloundecane stabilomer. J Med Chem 42 (1977) 3852-3859
60. Oliver D.W., Dekker T.G., Snyckers F.O., and Fourie T.G. Synthesis and biological activity of D3-trishomocubyl-4-amines. J Med Chem 34 (1991) 851-854
61. Oliver D.W., Dekker T.G., and Snyckers F.O. Antiviral properties of 4-amino-(D3)-trishomocubanes. Arzneimittelforschung 41 (1991) 549-552
62. Singh V., and Thomas B. Recent developments in general methodologies for the synthesis of linear triquinanest. Tetrahedron 54 (1998) 3647-3692
63. Liebenberg W., Van Rooyen P.H., and Van Der Schyf C.J. The biological activity of two symmetric amine derivatives of the cis-syn-cis triquinane system. Pharmazie 51 (1996) 20-24
64. Bezuidenhout L.M., Geldenhuys W.J., Malan S.F., and Van der Schyf C.J. Polycyclic amine derivatives: The synthesis of triquinylamines as calcium modulators (2007) Poster, American Chemical Society, 233rd National Meeting, Chicago, IL
65. Schleyer P.v.R. A simple preparation of adamantane. J Am Chem Soc 79 (1957) 3292
66. Marchand A.P. Chemistry. Diamondoid hydrocarbons-delving into nature's bounty. Science 299 (2003) 52-53
67. Tilley J.W., and Kramer M.J. Aminoadamantane derivatives. Prog Med Chem 18 (1981) 1-44
68. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5 (2006) 160-170
69. Chen H.S., and Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 97 (2006) 1611-1626
70. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
71. Kemp J.A., and McKernan R.M. NMDA receptor pathways as drug targets. Nat Neurosci 5 suppl (2002) 1039-1042
72. Choi Y.B., Tenneti L., Le D.A., et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci 3 (2000) 15-21
73. Wang Y., Eu J., Washburn M., et al. The pharmacology of aminoadamantane nitrates. Curr Alzheimer Res 3 (2006) 201-204
74. Igumnova N.D., Lemina E., Bitiukova I.I., Klimova N.V., and Skoldinov A.P. [Hydrolysis by plasma cholinesterase of complex adamantyl-containing esters]. Farmakol Toksikol 51 (1988) 38-41
75. Tsuzuki N., Hama T., Kawada M., et al. Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety. J Pharm Sci 83 (1994) 481-484
76. Gerzon K., Krumkalns E.V., Brindle R.L., Marshall F.J., and Root M.A. The Adamantyl Group in Medicinal Agents. I. Hypoglycemic N-Arylsulfonyl-N′ -Adamantylureas. J Med Chem 6 (1963) 760-763
77. Gerzon K., Kau D., and The adamantoyl function as a protecting group. The adamantyl group in medicinal agents. 3. Nucleoside 5′-adamantoates. J Med Chem 10 (1967) 189-199
78. Lavreysen H., Janssen C., Bischoff F., Langlois X., Leysen J.E., and Lesage A.S. [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol 63 (2003) 1082-1093
79. Schreiner E.P., Wolff B., Winiski A.P., and Billich A. 6-(2-adamantan-2-ylidene-hydroxybenzoxazole)-O-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg Med Chem Lett 13 (2003) 4313-4316
80. Abou-Gharbia M.A., Childers Jr. W.E., Fletcher H., et al. Synthesis and SAR of adatanserin: novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT(1A) and 5-HT(2) activity as potential anxiolytic and antidepressant agents. J Med Chem 42 (1999) 5077-5094
81. Augeri D.J., Robl J.A., Betebenner D.A., et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 5025-5037